Study to Investigate the Benefits of Dietary Supplement Quercetin for Early Symptoms of COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Testing negative for SARS-CoV-2 by RT-PCR with symptoms improvement
研究概览
简要总结
Quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables. It has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties. It is widely used to boost the body immune system against infections and keeping healthy life-style. The purpose of the present study is to investigate the potential benefits of quercetin for preventing COVID-19 disease progression and symptoms improvement in the early stage of infection.
详细描述
The strong antioxidant and anti-inflammatory properties of quercetin are closely related to its effective fight against a variety of disease conditions related to inflammation, including: viral infections, allergies, asthma, hay fever, arthritis, respiratory diseases, "hardening of the arteries" (atherosclerosis), high cholesterol, heart disease and circulation problems, insulin resistance and diabetes, eye-related disorders, including cataracts, stomach ulcers, cognitive impairment, gout, cancer, chronic fatigue syndrome, inflammation of the prostate, bladder, and ovaries, chronic infections of the prostate, skin disorders, including dermatitis and hives. Quercetin can help stop damaging particles in the body known as free radicals, which damages the cells by natural oxidation processes. It can also reduce the expression of inflammatory genes in the cells.
Quercetin has been shown to be effective against broad range of viruses including human respiratory syncytial virus (hRSV), rhinovirus, echovirus, coxsackievirus, poliovirus, parainfluenza type 3, Herpes Simplex Virus-1, cytomegalovirus, SARS-CoV-1, dengue virus, and Hepatitis C virus.
The purpose of the present study is to investigate the potential benefits of quercetin for preventing COVID-19 disease progression and improving symptoms in the early stage of infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 18 years of age or older, of either gender
- •Patients must be tested positive for SARS-CoV-2 by RT-PCR
- •Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.
- •Patients must be in the early stage of COVID-19 disease who do not require hospitalisation at the time of screening
- •Patients must be under the care of a Physician for diagnosis of COVID-19
- •Patients who have signed informed consent
排除标准
- •Patients with proven hypersensitivity or allergic reaction to quercetin
- •Patients with known chronic kidney disease with estimated creatinine clearance < 50 mL/minute or need for dialysis
- •Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure
- •Patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/L);
- •Pregnant patients
- •Patients declining to participate
研究组 & 干预措施
Standard of care (SOC)
This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
干预措施: standard of care for COVID-19 as per the hospital guidelines (Drug)
Quercetin
This arm will receive standard of care + oral Quercetin for two weeks
干预措施: standard of care for COVID-19 as per the hospital guidelines (Drug)
Quercetin
This arm will receive standard of care + oral Quercetin for two weeks
干预措施: Quercetin Phytosome (QP) (Dietary Supplement)
结局指标
主要结局
Testing negative for SARS-CoV-2 by RT-PCR with symptoms improvement
时间窗: From day 1 to day 14
次要结局
- Percentage of subjects that require hospitalisation(From day 1 to day 14)
- Improvement in CRP(From day 1 to day 14)
- Improvement in D-Dimers(From day 1 to day 14)
- Improvement in LDH(From day 1 to day 14)
- Improvement in Ferritin(From day 1 to day 14)
- Improvement in CBC(From day 1 to day 14)